Inhibition of colorectal cancer genomic copy number alterations and chromosomal fragile site tumor suppressor FHIT and WWOX deletions by DNA mismatch repair by Jahid, Sohail et al.
Inhibition of colorectal cancer genomic
copy number alterations and chromosomal
fragile site tumor suppressor FHIT and
WWOX deletions by DNA mismatch repair
The Harvard community has made this
article openly available.  Please share  how
this access benefits you. Your story matters
Citation Jahid, Sohail, Jian Sun, Ozkan Gelincik, Pedro Blecua, Winfried
Edelmann, Raju Kucherlapati, Kathy Zhou, Maria Jasin, Zeynep
H. Gümüş, and Steven M. Lipkin. 2017. “Inhibition of colorectal
cancer genomic copy number alterations and chromosomal
fragile site tumor suppressor FHIT and WWOX deletions by DNA
mismatch repair.” Oncotarget 8 (42): 71574-71586. doi:10.18632/
oncotarget.17776. http://dx.doi.org/10.18632/oncotarget.17776.
Published Version doi:10.18632/oncotarget.17776
Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34492232
Terms of Use This article was downloaded from Harvard University’s DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at http://
nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAA
Oncotarget71574www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/              Oncotarget, 2017, Vol. 8, (No. 42), pp: 71574-71586
Inhibition of colorectal cancer genomic copy number alterations 
and chromosomal fragile site tumor suppressor FHIT and WWOX 
deletions by DNA mismatch repair
Sohail Jahid1,*, Jian Sun1,*, Ozkan Gelincik1, Pedro Blecua8, Winfried Edelmann2, 
Raju Kucherlapati3, Kathy Zhou4, Maria Jasin5, Zeynep H. Gümüş6,7 and Steven M. 
Lipkin1
1Departments of Medicine and Genetic Medicine, Weill Cornell Medicine, 10021, NY, USA 
2Department of Cell Biology and Department of Genetics, Albert Einstein College of Medicine of Yeshiva University, 10461, 
NY, USA 
3Department of Genetics, Harvard Medical School, 02115, Boston, MA, USA
4Department of Biostatistics and Epidemiology, Weill Cornell Medical College, 10021, NY, USA 
5Developmental Biology Program, Memorial Sloan Kettering Cancer Center, 10065, NY, USA 
6Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 10029, NY, USA 
7Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, 10029, NY, USA 
8Division of Clinical Genetics, Memorial Sloan Kettering Cancer Center, 10065, NY, USA 
*These authors contributed equally to this work
Correspondence to: Steven M. Lipkin, email: stl2012@med.cornell.edu 
Zeynep H. Gümüş, email: zeynep.gumus@mssm.edu
Keywords: mismatch repair, homologous recombination, homeologous recombination, colorectal cancer
Received: January 16, 2017    Accepted: April 24, 2017    Published: May 10, 2017
Copyright: Jahid et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Homologous recombination (HR) enables precise DNA repair after DNA double 
strand breaks (DSBs) using identical sequence templates, whereas homeologous 
recombination (HeR) uses only partially homologous sequences. Homeologous 
recombination introduces mutations through gene conversion and genomic deletions 
through single-strand annealing (SSA). DNA mismatch repair (MMR) inhibits HeR, 
but the roles of mammalian MMR MutL homologues (MLH1, PMS2 and MLH3) proteins 
in HeR suppression are poorly characterized. Here, we demonstrate that mouse 
embryonic fibroblasts (MEFs) carrying Mlh1, Pms2, and Mlh3 mutations have higher 
HeR rates, by using 7,863 uniquely mapping paired direct repeat sequences (DRs) in 
the mouse genome as endogenous gene conversion and SSA reporters. Additionally, 
when DSBs are induced by gamma-radiation, Mlh1, Pms2 and Mlh3 mutant MEFs have 
higher DR copy number alterations (CNAs), including DR CNA hotspots previously 
identified in mouse MMR-deficient colorectal cancer (dMMR CRC). Analysis of The 
Cancer Genome Atlas CRC data revealed that dMMR CRCs have higher genome-wide 
DR HeR rates than MMR proficient CRCs, and that dMMR CRCs have deletion hotspots 
in tumor suppressors FHIT/WWOX at chromosomal fragile sites FRA3B and FRA16D 
(which have elevated DSB rates) flanked by paired homologous DRs and inverted 
repeats (IR). Overall, these data provide novel insights into the MMR-dependent HeR 
inhibition mechanism and its role in tumor suppression.
INTRODUCTION
DNA mismatch repair (MMR) is pivotal in 
maintaining genomic stability in both prokaryotes and 
eukaryotes. There are nine mammalian MMR genes, 
including E. coli MutS homologues (MSH6), MutL 
homologues (MLH1, MLH3) and yeast post-meiotic 
segregation homologues (PMS1 and PMS2) [1–5]. In 
humans, MLH1, MSH2, MSH6 and PMS2 mutations increase 
susceptibility to multiple malignancies, most notably 
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colorectal and endometrial cancers [1]. Mechanistically, 
mammalian MSH2-MSH6 and MSH2-MSH3 complexes 
form ‘sliding clamps’ that scan genomic DNA for sequence 
mismatches [6–9]. MSH2-MSH6 complex binds to single 
base-base mismatches and small insertions/deletion loops 
(IDLs), whereas MSH2-MSH3 complex is involved in 
the repair of larger IDLs [1] (IDL repair deficiency is 
commonly referred to as Microsatellite Instability, MSI). 
The MSH proteins interact with multiple proteins including 
the mammalian E.coli MutL homologues (MLH) and yeast 
post-meiotic segregation (PMS) homologue proteins, which 
have significant amino acid identity and structural similarity 
to the MLH proteins, among others (reviewed in [1]). 
The MLH1-PMS2 complex is the primary MutL 
heterodimer that interacts with both MSH2-MSH6 and 
MSH2-MSH3 complexes, and is the only heterodimer that 
participates in repair of single base substitutions. There is 
partial redundancy in the functions of MLH1-PMS2 and 
MLH1-MLH3 complexes in IDL repair and DNA damage 
response [10, 11]. In meiosis, both MLH1-PMS2 and 
MLH1-MLH3 complexes promote recombination-mediated 
cross-over events [12–14], and MLH1-PMS2 also plays 
roles in antibody class switch recombination [15]. A third 
MutL complex, MLH1-PMS1, has also been reported, but 
its role in mammalian MMR is yet to be clearly defined. 
HR is a critical pathway for repair of DNA double-
strand breaks (DSBs). Briefly, in mammals recA-like 
protein (Rad51) forms complexes with single-stranded 
DNA (ssDNA) strands. Rad51-ssDNA filaments interact 
with double stranded DNA (dsDNA) and pair when 
homologous sequence contacts are made. Subsequently, 
strand exchange occurs and a hybrid dsDNA/ssDNA 
complex called a D-loop is formed that is processed by 
multiple HR sub-pathways, including double-strand 
break repair (DSBR), synthesis dependent strand 
annealing (SDSA) and break-induced replication (BIR) 
[16]. DSBR, SDSA and BIR all produce copy number-
neutral HR repair. In contrast, when repetitive sequences 
flank a DSB, the mechanism of single strand annealing 
(SSA) can also be used for DSB repair [17]. SSA involves 
direct annealing between misaligned homologous repeat 
sequences and ssDNA recession. Consequently, SSA at 
repetitive homologous motifs causes deletion of one repeat 
sequence and the intervening sequences between repeats, 
resulting in deletion copy number alterations (CNAs). 
When flanked by direct repeats (DRs) or inverted repeats, 
DSBs stimulate HR and SSA several hundred fold [18]. 
Relatively small degrees of sequence heterogeneity 
can alter the frequency of DSB-induced HR and SSA in 
mammalian cells. For example, HR is decreased by >80% 
for DRs that are 1.2% divergent [19]. When the donor and 
recipient sequences are highly similar but not identical 
(homeologous), the repair process is referred as homeologous 
recombination (HeR) [16]. MMR proteins play important 
roles in preventing HeR and SSA. Specifically, MMR 
recognizes and repairs mismatches in DNA heteroduplex 
regions (regions that are formed by annealing single strands 
from different sources), removes non-homologous tails 
during HeR repair and disrupts HeR repair via heteroduplex 
rejection or anti-recombination (recently reviewed in [16]).
MMR suppression of HeR was first observed in 
bacteria [20, 21] where it prevents rotation of mismatched 
DNA strands [22], and was subsequently found to occur 
in eukaryotes [23]. In the yeast Saccharomyces cerevisiae, 
functional mutations of Msh2p, Msh6p, Mlh1p or Pms1p 
(orthologues of mammalian PMS2) increase HeR between 
integrated reporters containing DRs with mismatch 
heterology [23–26], yet roles for Mlh2p/Mlh3p are 
poorly characterized. Additionally, individual functional 
mutations of Msh2p, Mlh1p or compound mutations 
of the three Mlh1p heterodimeric partners, Pms1p/
Mlh2p/Mlh3p, increases SSA [27]. In mammalian cells, 
MutS homologues MSH2 and MSH6 can suppress HeR 
[24, 28–31], but the role of mammalian MutL homologues 
in mechanisms inhibiting HeR is less well characterized. 
Furthermore, whether or not the overall increased HeR and 
SSA rates from loss of MMR contribute to tumorigenesis 
is poorly understood. 
In tumors, DSBs also occur frequently at 
chromosomal fragile sites (CFS). CFS are AT-rich 
repetitive sequences that are difficult-to-replicate during 
mitosis and manifest as gaps flanked by DSBs in different 
tumors [32–35]. Fragile sites FRA16D and FRA3B have 
increased DSB rates and are the most common CFS 
reported in tumors [36–39]. FRA3B and FRA16D are 
evolutionarily conserved across eukaryotes [36] and 
encode the tumor suppressors 
FHIT and WWOX, respectively. Fragile histidine 
triad protein (FHIT) (also called bis(5′-adenosyl)-
triphosphatase) spans 10 exons over a 1Mb region at fragile 
site FRA3B. FHIT is a member of histidine triad subfamily 
of nucleotide binding proteins. FHIT is a DNA hydrolase 
that metabolizes substrate AP3A (diadenosine 5-prime,5-
triple prime-P(1),P(3)-triphosphate), which promotes DNA 
replication and inhibits stress response signaling [40]. CRCs 
and gastric carcinomas with MMR deficiency frequently 
also carry large deletions in FHIT  [41]. FHIT deletions also 
frequently occur in lung cancer [36, 42] Fhit knockout mice 
develop gastric carcinomas and skin cancers [43, 44].
WWOX is a WW domain-containing 
oxidoreductase at FRA16D. WWOX contains 9 
exons and spans 1.2 Mb [43]. Genomic deletions and 
other structural variants inactivating WWOX occur 
in almost one-third of solid tumors [45, 46]. WWOX 
suppresses TGFβ/SMAD signaling [46], and WWOX 
mouse mutants promote mammary tumor growth [36]. 
While loss of MMR in CRCs has been associated 
with increased frequency of FHIT [47] and WWOX 
[48] deletions, inactivation of FHIT and WWOX at 
FRA3B and FRA16D CFS has not been linked to HeR. 
Here, we report that mammalian MutL homologs 
MLH1, PMS2 and MLH3 participate in suppression 
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of HeR and SSA. In addition to GFP reporter studies, 
we computationally identified 6,848 paired DRs with 
97%–99.9% sequence identity mapping to unique locations 
in the mouse genome as substrates for endogenous 
genomic HeR and SSA. Confirming reporter gene studies 
in yeast, we demonstrate that mutation of Mlh1, Pms2, 
Mlh3 or Mlh3/Pms2 increases HeR in MEF DR sequences. 
Furthermore, for the 1–12 heterologous bases in each 
paired DR, we show that >94% of base substitution 
mutations are consistent with gene conversion (where a 
mismatched base in one direct repeat motif is replaced 
with its respective paired direct repeat heterologous 
base). Next, to assess SSA, we used gamma-irradiation to 
promote endogenous DSBs and show that Mlh1, Pms2 and 
Mlh3 mutations suppress CNAs, including recurrent CNA 
hotspots that we previously identified in mouse dMMR 
intestinal tumors. Finally, we analyze data from dMMR 
and MMR proficient (pMMR) CRCs with matched normal 
tissues from The Cancer Genome Atlas (TCGA) (http://
cancergenome.nih.gov). These studies confirm high rates 
of human endogenous paired DR HeR and reveal that the 
intervening sequences between paired DRs are deleted 
more frequently in dMMR vs pMMR CRCs. Specifically, 
these dMMR recurrent CNA deletions include hotspots at 
chromosomal fragile sites FRA3B and FRA16D, which 
have flanking DR and IR sequences and high rates of 
spontaneous DSBs in CRCs. Overall, these data provide 
insights into mammalian MutL homolog inhibition of 
HeR and SSA and are consistent with a potential role for 
dMMR inhibition of homeologous recombination in tumor 
suppression.
RESULTS
Mlh1, Pms2 and Mlh3 suppress direct repeat 
motif reporter gene homeologous recombination 
To understand the role of mammalian MutL 
homologues in HR and HeR, we modified the pDR-GFP 
homologous recombination reporter by introducing eight 
closely spaced mutations in GFP to monitor homeologous 
recombination, similar to neomycin-based reporters 
previously used to study the role of mammalian MSH2 
in HeR [28] (Supplementary Figure 1). These reporters 
have 5′ and 3′ overlapping fragments of GFP in the same 
orientation with intervening puromycin selection cassette 
and a double stranded nuclease (I-SceI) binding site 
between the direct repeats. DR-GFP has 100% identity 
between overlapping sequences and DR-GFP8mu has 
8 point mutations (1.2% heterology). Upon transient 
expression of I-SceI, a double strand break is induced in 
cells. DR-GFP and DR-GFP8mu (or pneo-Wt and pneo-
8 mu) can be repaired by HR/HeR or SSA and scored 
as GFP+ or GFP- expressing cells by flow cytometry or 
neomycin positive cells in colony selection assay. We used 
these reporters for exploratory experiments in wild-type 
(Wt), Mlh1-/-, Pms2-/-, Mlh3-/-, and Pms2-/-;Mlh3-/- 
mouse embryonic fibroblasts (MEFs) matched for passage 
number.
In Wt MEFs transfected with I-SceI, comparisons 
of DR-GFP and DR-GFP8mu stable transfectants showed 
that 1.2% heterology suppressed HeR vs HR by 74 ± 3%, 
whereas MLH1-/- MEFs showed only 3 ± 4% suppression 
(Supplementary Figure 2) (P = 0.005, ANOVA followed by 
Dunnet’s test). Further experiments in Mlh3-/-, Pms2-/- and 
Pms2-/-;Mlh3-/- MEFs showed 77.5 ± 0.5%, 60 ± 5% and 
13.5 ± 0.5% HeR suppression relative to HR (all p < 0.001, 
ANOVA followed by Dunnet’s test). These studies are 
consistent with a potential role for mouse Mlh1 in HeR 
suppression. Similar to previous findings in IDL repair 
and DNA damage response, these data also are consistent 
with partially redundant roles for PMS2 and MLH3 in 
HeR suppression, as results in Mlh1-/- MEFs were not 
significantly different from those in Mlh3-/-;Pms2-/- MEFs 
(P = 0.74, ANOVA followed by Dunnet’s test).
Identification of paired direct repeats in the 
mouse genome
To understand the roles of MutL homologues in 
HeR suppression of endogenous direct repeat sequences, 
we computationally identified paired DR motifs in the 
mouse genome with uniquely mapping locations and 
characteristics similar to DR-GFP8mu and DR-Neomut8 
reporters. Using the Vmatch program [49], we identified 
7,863 mouse DR pairs with the following parameters: 5′ 
and 3′ DR motifs each > 480 bp in the same orientation 
with 1–12 mismatched pairs (97%–99.9% identity) and 
intervening sequences ranging from 500bp to 50 kb 
(Supplementary Figure 3 and Supplementary Table 1). 
The average length of paired DRs is 720bp, ranging from 
500 bp to 22,359 bp (chr5:105039588-105061946 and 
105092514-105114872). The average intervening sequence 
between paired DRs is 2,157 bp, with the largest 49,972 bp 
(chr15:74830812-74880784). The set of DRs with 97%–
99.9% identity covers 5,035,586bp in the mouse genome. 
There are 1,031 DRs that overlap with protein coding 
exons. Chromosome 7 has the highest density of DRs (734/
Mbp), while chromosome 16 has the lowest (79/Mbp).
Mouse genome paired direct repeats have high 
rates of endogenous homeologous recombination 
and SSA
DSBs that occur between DRs stimulate both HR 
and SSA [50]. To understand the role of individual MutL 
homologues in suppression of HeR and SSA, we treated 
MEFs with γ-irradiation and cultured for two additional 
passages. Subsequently, we performed targeted capture 
of DNA from control and irradiated MEFs for the DR 
sequences from Mlh1-/-, Pms2-/-, Mlh3-/-, Mlh3-/-
;Pms2-/- and Wt MEFs that are all derived from C57B/
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L6 genetic background and matched for passage number 
(n = 25). Targeted DR sequences were then analyzed on 
an Illumina HiSeq 2500. After mapping sequence reads to 
mouse genome (mm9), and filtering DR reads for mapping 
quality score >23 and sequence read depth >10 reads, we 
successfully obtained sequence data for 5,119 paired DR 
for further analysis. 
We compared log-transformed and normalized 
mutation rates for each MEF genotype, both control and 
irradiated using multiple linear regression. The analysis 
revealed no systematic difference in mutation rates with 
irradiation induced DSBs (P > 0.15; ANOVA followed 
by Dunnet’s test). Compared with Wt MEF DRs, Mlh3-/-, 
Pms2-/-, Mlh3-/-;Pms2-/- and Mlh1-/- MEF DRs all had 
significantly higher mutation rates (all P < 0.001; ANOVA 
followed by Dunnet’s test) (Table 1).
Next, we separately compared mutations at 
heterologous bases that differed between 5′ and 3′ regions 
of paired DRs (HeR-BP) and surrounding bases (non-HeR-
BP) in DRs with no CNAs. HeR-BPs in DR sequences had 
significantly higher mutation rates than surrounding bases 
(Table 1) ranging from 18 to 40 fold higher respectively 
(all P < 0.001; ANOVA followed by Dunnet’s Test). In 
both Wt and dMMR MEFs, for mutations occurring 
at HeR-BPs, more than 94% of changes were at the 
corresponding base in the paired DR (e.g. if paired 5′ 
and 3′ DR HeR-BP sequences are gggCtaa and gggTtaa 
respectively, the corresponding heterologous mutation 
in the 3′DR consistent with gene conversion would be 
gggCtaa) (Figure 1).
The percentage of DR HeR-BP mutations 
consistent with gene conversion is significantly higher 
than chance (Table 1; Supplementary Table 1) for 
all MEF genotypes analyzed. This observation was 
consistent in both 5′ to 3′ and 3′ to 5′ direction paired DR 
sequence gene conversions (all P < 0.001, Chi-square). 
Similarly, for longer gene conversion tracts that include 
two consecutive heterologous bases with mutations 
consistent with gene conversion, we observed that Mlh3, 
Pms2, Mlh1 or combined Mlh3/Pms2 mutations also 
significantly increased the number of tracts vs Wt MEFs 
(Table 1). Overall, among the universe of mouse genome 
DRs, mutation of Mlh1, Pms2, Mlh3 or Mlh3/Pms2 
significantly increased HeR-BP mutation rates consistent 
with gene conversion for mouse genome paired DRs vs 
Wt MEFs (all P<0.001, ANOVA followed by Dunnet’s 
Test) (Table 1). In conclusion, these data are consistent 
with high rates of endogenous gene conversion in mouse 
genome paired DR sequences in both Wt and dMMR 
MEFs. Individual functional mutations of Mlh3, Pms2, 
Mlh3 and Pms2 or Mlh1 all further increased rates of 
mutations significantly, consistent with gene conversion 
in DRs at HeR-BP, as well as overall mutation rates in 
non-HeR-BP. Mutation rates at HeR-BP were significantly 
higher than non-HeR-BP bases in DR sequences. Mlh1 
mutation caused the greatest increase in HeR-BP and non-
HeR-BP, but individual Mlh3, Pms2 or combined Mlh3 
and Pms2 mutations resulted in similar increases (Table 1). 
Increased DR copy number alterations caused by 
γ-irradiation induced DSBs in Mlh1, Pms2 and 
Mlh3 mutant MEFs
Previously, we identified dMMR enriched recurrent 
CNAs in mouse Mlh3-/-;Pms2-/- intestinal tumors 
on chromosomes 7 and 12, which were not present in 
paired normal mucosa [10]. To understand the role of 
different mammalian MutL homologues in suppression 
of mouse genomic DR SSA and CNA generation, we 
compared paired DR sequence read depth of control 
to γ-irradiated MEFs. Mlh3-/- and Pms2-/- MEFs had 
significantly increased DR CNA rates, predominantly 
deletions, vs Wt MEFs (P = 1.08 × 10-12 and P = 0.0203; 
Chi-square), as did Mlh3-/-Pms2-/- and Mlh1-/- MEFs 
(P = 5.91 × 10-13 and 2.22 × 10-115) (Figure 2; 
Supplementary Table 3). Importantly, Mlh1-/- MEFs 
had overall increased CNA rates vs all other MutL 
deficient MEFs tested, including Mlh3-/-;Pms2-/- (all 
p < 1.09 × 10-6; ANOVA followed by Dunnet’s Test). 
Strikingly, shared DR deletion hotspots were observed 
on mouse chromosomes 6 and 7 (chr6: 89127070-
114500739 and chr7: 3957350-3958737; Figure 2). The 
chromosome 6 CNA deletion hotspot was observed in 
Mlh3-/-, Mlh3-/-;Pms2-/- and Mlh1-/- MEFs, but not 
Pms2 mutants, whereas the chromosome 7 CNA deletion 
cluster hotspot was observed in all MutL mutant MEFs 
tested (Figure 2). Additionally, in Mlh1-/- MEFs, a DR 
CNA amplification hotspot was observed on chromosome 
12 (chr12: 114392088-117316196) (Figure 2). Cross-
comparison of these data with previous genome-wide 
array comparative genomic hybridization (aCGH) studies 
of dMMR Mlh3-/-;Pms2-/- intestinal tumors vs paired 
normal mucosa revealed that the observed irradiated 
MEF CNA chromosome 7 and chromosome 12 hotspots 
overlapped with previously observed hotspot regions in 
Mlh3-/-;Pms2-/- intestinal tumors [10]. 
In summary, mutation of Mlh3, Pms2 or Mlh1 each 
significantly increased DR CNA rates in γ-irradiated 
MEFs. Each MutL mutation caused a bias towards genomic 
deletions, likely due to increased SSA between homologous 
DR sequences. Mlh1-/- MEFs overall had increased CNA 
rates vs Mlh3, Pms2 or combined Mlh3;Pms2 mutations. 
On chromosome 6, an Mlh3 mutation dependent CNA 
deletion hotspot was observed that was also seen in Mlh1-
/- but not Pms2-/- irradiated MEFs. A chromosome 7 
CNA deletion hotspot shared by Mlh3, Pms2 and Mlh1 
mutant MEFs was also seen that had been previously 
identified in Mlh3-/-;Pms2-/- deficient intestinal tumors. 
Furthermore, an Mlh1 (but not other MutL homologue) 
mutation dependent chromosome 12 CNA amplification 
hotspot, which had also been previously identified in Mlh3-
/-;Pms2-/- intestinal tumors, was observed.  
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Figure 1: Overview of mouse genome direct repeat sequences. (A) Schematic illustration of part of a 5′ and 3′ paired direct 
repeat (DR) sequence with 3 non-identical basepairs that can be monitored for HeR. Non-identical basepairs are shown in red and green. 
(B) Distribution of 5,119 paired DRs in the mouse genome. Red indicates location of a paired DR. Also see Supplementary Figure 3 for the 
distribution of DRs for each chromosome for mouse and human genomes. Figure was generated using PhenoGram1 [73]. 
Figure 2: Copy number alterations in direct repeat motifs after irradiation induced double strand breaks. Y-axis shows 
log2 ratio of read depth comparing pre- and post-irradiated DRs. X-axis shows chromosomal location of each DR. MEF genotypes are 
indicated on the right. Red bars indicate CNAs in chromosome 6, 7 (deletions) and 12 (duplications).
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Table 1: DR mutation rates and homologous recombination in dMMR MEFs 
MEF Phenotype Overall DR mutations 
Mutations at 
specific DR sites
Mutations 
outside specific 
DR sites
GC consistent 
mutations at 
specific DR sites 
GC inconsistent 
mutation at 
specific DR sites 
% of GC-consistent 
mutations at specific 
DR sites
GC consistent 
mutations at two 
contiguous DR sites 
Wt 5.9 118.7 4.1 115.8 2.9 97.55686605 8.7
Irradiated Wt 7.1 99.9 5.6 96.9 2.9 96.996997 8.8
Mlh3−/− 41.6 1000.4 25.9 961.3 39.1 96.09156337 58.7
Irradiated Mlh3−/− 42.5 1015.1 26.7 976.2 38.9 96.16786523 55.1
Pms2 −/− 43.1 959.5 28 907.2 52.3 94.5492444 64.6
Irradiated Pms2 −/− 42.4 953.4 27.5 904.1 49.4 94.82903293 58.6
Mlh3 −/− ; Pms2 −/− 44.1 1021.7 28.1 983 38.7 96.21219536 67.7
Irradiated Mlh3 −/− ; 
Pms2 −/− 
45.1 1040 28.9 997.9 42.1 95.95192308 77.8
Mlh1 −/− 61.2 1370.3 40 1306.8 63.5 95.36597825 118
Irradiated Mlh1 −/− 67.1 1574.1 42.5 1523.5 50.7 96.78546471 136.2
Note: For all above, mutation rates were calculated per 10000 bp.
Human dMMR CRC paired DRs have increased 
rates of homeologous recombination 
Using the same methodology and parameters for 
analysis as in the mouse genome, we identified 12,379 
uniquely mappable DRs in the human genome, each 
carrying 1-12 heterologous bases per paired DR. We then 
evaluated whether MMR mutations increased paired DR 
HeR rates in matched normal mucosa-dMMR patient CRC 
by analyzing genome sequence data from The Cancer 
Genome Atlas (TCGA-COAD) [51]. We identified 10 
dMMR CRCs with matched normal-tumor whole genome 
sequence with >30× average sequence coverage, and 
compared them to 10 consecutive pMMR CRCs in TCGA-
COAD for somatic mutations in DRs. 
As expected, dMMR CRCs have significantly higher 
mutation rates in DRs (1.36 × 10-4 vs 3.7 × 10-4 p < 0.001, 
chi-square test) (Table 2). Similar to our findings in DRs 
in mouse genome, in the human CRCs HeR-BP in DRs 
have significantly higher mutation rates than surrounding 
bases (mean 9.75 fold increase, p < 0.001, chi-square test). 
Secondly, consistent with gene conversion and similar to 
our findings in mouse MEFs, HeR-BP in TCGA dMMR 
and pMMR CRCs were found to be significantly enriched 
for the corresponding base substitution in their matched 5′ 
or 3′DRs (92.86% in dMMR CRCs and 95.44% in pMMR 
CRCs respectively, all p < 0.001, Chi Square test) (Table 2). 
HeR-BP mutations consistent with gene conversion were 
also significantly higher in dMMR vs pMMR CRCs 
(1.02 × 10-3 vs 3.2 × 10-4 respectively, Chi Square test). 
Additionally, dMMR CRCs also had higher rates of tracts 
consisting of two consecutive heterologous bases both with 
gene conversion consistent mutations (Table 2).
Overall, these human CRC data are consistent with 
studies in mouse MEFs and DRs in the mouse genome. 
In human DRs, both HeR-BPs and surrounding bases 
have overall elevated mutation rates when dMMR is 
compared to pMMR CRCs. However, HeR-BPs have 
higher mutation rates than surrounding DR bases, almost 
all mutations are consistent with a mechanism of gene 
conversion in both pMMR and dMMR CRCs, including 
tracts of gene conversion consistent mutations. Moreover, 
dMMR CRCs have higher HeR rates than pMMR CRCs. 
Human dMMR CRC deletion hotspots are at 
chromosomal fragile sites encoding FHIT and 
WWOX
To understand whether dMMR CRCs have 
CNA hotspots similar to what we observed in MEFs, 
we investigated the distribution of genomic regions 
preferentially deleted only in dMMR CRCs as potential 
sites for SSA mediated genomic deletions. By comparing 
CNA deletion rates in 32 dMMR and 156 pMMR 
tumors, we found that the ratio of CNA deletions in 
DRs and intervening sequences compared to non-DR 
sequences is significantly higher in dMMR vs. pMMR 
tumors (Wilcoxon rank sum test P = 0.00947). Of 
note, this analysis also revealed two dMMR somatic 
deletion hotspots that mapped to FRA3B and FRA16D 
chromosomal fragile sites (CFS) (Figure 3). CFS are 
long AT-rich repeat genomic sequences that are sites of 
DNA polymerase stalling during genome replication and 
have very high rates of spontaneous DSBs in tumors. 
When DSBs occur at CFS, homologous recombination 
is known to play an important role in CFS repair. Loci 
FRA3B and FRA16D, which encode the tumor suppressor 
genes FHIT and WWOX respectively, are the two most 
frequently deleted chromosomal loci in human CRCs. 
Furthermore, higher rates of FHIT and WWOX deletions 
have previously been reported in dMMR and pMMR CRC 
cell lines and tumors [52–58].
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Figure 3: Increased somatic deletions at chromosomal fragile sites FRA3B and FRA16D in dMMR human CRCs. 
Density distribution (number/MB) of deleted probes across all human autosomes in dMMR tumors. FRA3B and FRA16D outliers are 
indicated.
Table 2: DR mutation rates and homologous recombination in dMMR vs pMMR CRCs 
hCRC 
TCGA 
sample ID
Overall DR 
mutations 
Mutations at 
specific DR 
sites (HeR-BP)
Mutations 
outside specific 
DR sites (non-
HeR-BP)
GC consistent 
mutations at 
specific DR sites 
(HeR-BP)
GC inconsistent 
mutation at 
specific DR sites 
(HeR-BP)
% of GC-
consistent 
mutations at 
specific DR 
sites(HeR-BP)
GC consistent 
mutations at two 
contiguous DR 
sites (HeR-BP)
dMMR aa-3516 0.112 0.783 0.096 0.7 0.083 89.39974457 0.1056
aa-3518 0.101 0.524 0.09 0.5 0.024 95.41984733 0
d5-6540 0.093 0.805 0.076 0.748 0.058 92.91925466 0.1149
aa-a00r 0.102 0.561 0.09 0.463 0.098 82.5311943 0.119
aa-a01r 0.101 0.99 0.079 0.99 0 100 0.0359
a6-6781 0.097 1.082 0.074 1.022 0.059 94.45471349 0.0911
ad-6964 0.095 0.64 0.082 0.598 0.043 93.4375 0.0289
az-6601 0.093 0.868 0.075 0.821 0.046 94.58525346 0.1931
ad-a5ej 0.081 0.664 0.067 0.649 0.015 97.74096386 0
qg-a5z2 0.078 0.649 0.064 0.62 0.029 95.53158706 0
pMMR aa-3514 0.027 0.236 0.022 0.236 0 100 0
aa-3534 0.038 0.387 0.029 0.364 0.023 94.05684755 0
aa-a01x 0.021 0.249 0.015 0.228 0.021 91.56626506 0
ag-3593 0.032 0.357 0.023 0.357 0 100 0.0538
ag-3890 0.028 0.268 0.022 0.251 0.017 93.65671642 0
aa-3685 0.037 0.218 0.032 0.2 0.018 91.74311927 0
aa-a02y 0.028 0.229 0.023 0.229 0 100 0
aa-a01v 0.037 0.339 0.029 0.313 0.026 92.33038348 0
ad-a5ek 0.027 0.301 0.021 0.286 0.015 95.0166113 0
qg-a5z1 0.035 0.404 0.026 0.389 0.015 96.28712871 0
Note: For all above, mutation rates were calculated per 10000 bp.
Since FRA3B and FRA16D common chromosomal 
fragile sites have high rates of spontaneous DSBs, to 
understand whether increased SSA recombination between 
homologous repeat sequences could be a mechanism 
contributing to increased FRA3B and FRA16D CNA 
deletions in dMMR CRCs, we mapped each somatic 
deletion’s flanking breakpoints in genome sequence from 
13 TCGA-CoAD dMMR and 77 pMMR CRCs with 
matched normal tissues and mean sequence coverage 
>10×. Using Vmatch parameters requiring >80% identity 
for > 80 bp in length within 1kb of deletion breakpoints, 
we identified 4 and 0 paired DRs, and 1 and 0 inverted 
paired DRs respectively in dMMR vs. pMMR CRCs 
(38.4% vs 0%, P = 0.0001 chi-square test). These dMMR 
CRC genomic deletions were flanked by DR and IR 
motifs ranging in size from 46 kb to 338 kb (Figure 4; 
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Supplementary Table 4). Notably, these findings are 
consistent with high rates of spontaneous DSBs at the 
FRA3B and FRA16D chromosomal fragile sites in human 
dMMR CRCs that promote SSA and deletions at the FHIT 
and WWOX tumor suppressor loci. 
DISCUSSION
DNA mismatch repair plays critical roles 
in maintaining genome integrity and inhibiting 
tumorigenesis. For repetitive sequences, suppression 
of HeR and SSA are important mechanisms to maintain 
genomic integrity. However, the role of individual 
mammalian MutL homologues in preserving genomic 
integrity by suppressing HeR and SSA between similar 
DNA sequences is poorly characterized. Furthermore, the 
roles of HeR and SSA in tumor suppression are unclear. 
Building upon previous studies with HeR reporter 
genes [28], we demonstrate that genomic DRs can 
serve as in vivo endogenous reporters for measuring the 
levels of suppression or induction of HeR and SSA. In 
Wt MEFs, endogenous mutations in DRs are dominated 
by gene conversion, with HeR-BP mutation rates 33–40 
fold higher than surrounding bases and >94% consistent 
with gene conversion from the corresponding DR paired 
sequence. Loss of function mutations in Mlh1, Pms2, Mlh3 
and combined loss of function mutations in Mlh3;Pms2 
further increase rates of mutations significantly, which is 
consistent with gene conversion in DRs at HeR-BP, as well 
as overall mutation rates in non-HeR-BP. Using both GFP 
reporter and genomic DRs, we extend previous reporter 
gene based studies of Saccharomyces cerevisiae Mlh1p 
and Pms1p (ortholog of Pms2) [23–26] to mammalian 
cells and show that mouse MutL homologs Mlh1 and Pms2 
are involved in HeR suppression. Furthermore, we extend 
these findings and provide evidence for mammalian Mlh3 
involvement in HeR suppression as well (summarized in 
Supplementary Figure 4A).
We evaluated DR mutations in human dMMR 
and pMMR CRCs by using available whole genome 
sequencing data from the TCGA database (http://
cancergenome.nih.gov). In human genome DRs, HeR-BPs 
have higher mutation rates than surrounding DR bases. 
Almost all mutations are consistent with a mechanism 
of gene conversion in both pMMR and dMMR CRCs, 
including tracts of two consecutive gene conversion 
consistent mutations. Overall, these findings are largely 
consistent with MEF studies, supporting DRs as in vivo 
endogenous HeR reporters and demonstrating that dMMR 
CRCs have higher HeR rates than pMMR CRCs.
Next, using γ-irradiation to induce DSBs, we show 
that DR paired sequences can also be used to monitor 
SSA. Consistent with Saccharomyces cerevisiae Mlh1p 
reporter gene studies [27], loss of function mutations in 
Mlh1, Pms2 or Mlh3 each significantly increased DR CNA 
rates (summarized in Supplementary Figure 4B).
 For all mutant MEFs, there was a bias towards DR 
genomic deletions, which is most likely due to increased 
SSA between homologous DR sequences. Similarly, 
analysis of TCGA data also support increased rates of SSA 
in dMMR compared to pMMR in human CRCs. MMR 
deficiency increased the rate of CNA deletions for both DRs 
and the intervening sequences between matching DR pairs.
Interestingly, analysis of MEF showed that Mlh1-/- 
cells have significantly higher overall CNA rates compared 
to Pms2-/-, Mlh3-/- or even Mlh3-/-;Pms2-/- MEFs. While 
Figure 4: Somatic FRA3B (A) and FRA16D (B) genomic deletions (blue) and duplications (red) in dMMR and pMMR tumors. Analysis 
of whole genome sequencing (WGS) data of dMMR and pMMR human CRC tumors from TCGA-COAD. The rates of genomic deletions 
at FRA3B and FRA16D are significantly higher in dMMR than in pMMR human CRCs (p = 0.026 and p = 0.017, t-test). Blue lines indicate 
deletion, red lines indicate amplification.
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we did not have Pms2-/-;Mlh3-/-;Pms1 triple mutant 
MEFs to study, given that Mlh1-Pms2, Mlh1-Mlh3 and 
Mlh1-Pms1 constitute all known MutL complexes, our 
data suggest a potential previously unexplored role for the 
Mlh1-Pms1 MutL complex in suppression of SSA.
Unexpectedly, in both mouse MEF and human TCGA 
studies, we identified evidence of specific CNA hotspots. 
For MEF with DSBs induced by gamma irradiation, 
hotspots included (a) a mouse chromosome 6 deletion 
hotspot shared by Mlh1-/-, Pms2-/-, Mlh3-/- and Mlh3-/-
;Pms2-/- MEFs, (b) mouse chromosome 7 deletion hotspot 
shared by Mlh1-/-, Pms2-/-, Mlh3-/- and Mlh3-/-;Pms2-/- 
MEFs that we had been previously identified in Mlh3-
/-;Pms2-/- deficient intestinal adenocarcinomas but not 
matched normal mucosa or Mlh3-/- adenomas [10] and (c) 
a mouse chromosome 12 amplification hotspot in Mlh1-/- 
MEFs, also previously seen in Mlh3-/-;Pms2-/- deficient 
intestinal adenocarcinomas [10]. Each of these regions is 
rich in highly repetitive elements. The mouse chromosome 
6 deletion-hotspot occurs in a gene desert with no obvious 
unique feature, while the chromosome 7 hotspot contains 
a cluster of highly homologous paired immunoglobulin 
receptor (PiR) genes and the chromosome 12 hotspot 
contains many Immunglobulin Heavy chain (IgH) genes 
with a high degree of homology. We propose that mouse 
PiR and IgH gene clusters act as endogenous substrates for 
homeologous DR and inverted repeat (IR) formation. For 
chromosome 6 and 7 loci, the predominance of DR deletions 
is consistent with MutL suppression of SSA. However, for 
the chromosome 12 hotspot, there is a strong bias of CNAs 
to cause copy number gains. The precise mechanism of 
recombination at this latter locus and the precise features of 
each loci that specifically cause great dependence on MMR 
to suppress recombination are unclear at this time. 
In human CRCs, analysis of DRs and IRs revealed 
two somatic deletion dMMR hotspots at chromosomal 
fragile sites (CFS) FRA3B (chr3:58,600,000–63,700,000) 
and FRA16D (chr16:79,200,000–81,700,000). CFS are long 
AT-rich repeat genomic sequences that are sites of DNA 
polymerase stalling during genome replication and have very 
high rates of spontaneous DSBs in tumors [59–61]. When 
DSBs occur at CFS, homologous recombination is known 
to play an important role in CFS repair [62–65]. FRA3B 
and FRA16D, which encode the tumor suppressor genes 
FHIT and WWOX respectively, are the two most frequently 
deleted chromosomal loci in human CRCs. Higher rates of 
FHIT and WWOX deletions have previously been reported 
in dMMR vs pMMR CRC cell lines and tumors [66, 67]. 
Mapping revealed in dMMR CRCs higher rates of DR and 
IR motifs in breakpoints flanking FRA3B and FRA16D. 
Since CFS have high endogenous rates of DSBs, our data are 
consistent with increased rates of SSA promoting deletions 
of FHIT and WWOX tumor suppressors in dMMR tumor. 
In summary, known DNA mismatch repair tumor 
suppression mechanisms include base-substitution and 
small in/del mutation repairs as well as DNA damage 
response initiation. Our data provide the first evidence 
that homeologous recombination and SSA suppression 
are also important MMR tumor suppression mechanisms. 
Poly ADP (Adenosine Diphosphate)-Ribose Polymerase 
(PARP) inhibitors are an example of a successful 
mechanistically based therapy that exploits synthetic 
lethality with HR deficiency in ovarian and breast tumors. 
Our findings suggest that screens to identify drugs 
promoting synthetic lethality with increased HeR rates 
may similarly be effective for targeted treatment of dMMR 
tumors.
MATERIALS AND METHODS
Mouse embryonic fibroblast cell culture
Mouse embryonic fibroblasts were established from 
day 12.5 embryos isolated from the uteri of pregnant mice 
and matched for passage number as previously described 
[11]. In brief embryos were digested in Trypsin-EDTA 10 
minutes in an incubator (37°C; 5% CO₂) and washed with 
PBS. MEFS were then grown in 15% FBS and 100U/ml 
penicillin, 100 ug/ml streptomycin at 37C, 5% CO2. 
Mouse embryonic fibroblast transfection
We constructed pDR-GFP8mu containing 8 silent 
mutations in the iGFP of pDR-GFP [28]. Primary MEFs 
were transfected with either pDR-GFP or pDR-GFP8mu 
and pCβASc by electroporation using a Nucleofactor 
device. Briefly, 2 × 107 cells in 1 ml of phosphate-buffered 
saline were electroporated with 20 to 25 μg of each uncut 
plasmid DNA in a 0.4-cm electrode-gap cuvette (250 V, 
960 μF). Electroporated cells were aliquoted into four or 
five 10-cm-diameter dishes and kit for primary cells. As 
I-SceI is expressed and recombinant cells expressing GFP 
were analyzed using flow cytometry (BD-Biosciences) or 
colonies were selected in media 24 h after electroporation 
and were grown in selection G418 (200 μg/ml) media for 
14 days before colony counts.
MEF gamma irradiation
Primary MEFS from all cell lines were cultured and 
irradiated with 5 Grays @ 1.27 Gy/Min. Subsequently the 
cells were fed fresh media and allowed to grow and passaged 
twice. The cells were then harvested and genomic DNA was 
extracted using DNeasy kit (Qiagen) per manufacturer’s 
protocol. All experiments were performed by irradiating 
exponentially growing cell cultures with 137Cs irradiator 
(Mark 1 irradiator, JL Shepherd & Associates). 
Direct repeat region identification
To search for direct repeat (DR) regions in mouse 
genome (mm9) and human genome (hg19) we used the 
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program Vmatch [68] using the following parameters: 
minimal length of repeat region 480 bp, minimal gap 
between DR regions 500 bp, and maximal gap 50Kb; 
minimal sequence identity between paired DRs >97%, and 
maximum number of non-identical base pairs is 12/DR. 
Sequence analysis
Paired-end reads sequenced at targeted direct repeat 
regions were processed at Weill Cornell Genomic Core 
and then mapped to mouse reference genome (mm9) 
with BWA method [69]. After removing PCR duplicates, 
only uniquely mapped and properly paired reads were 
considered for depth calculation. Variants in the direct 
repeat regions were called with SAMtools software [70]. 
These variants were then filtered with standard thresholds 
for quality (q30), depth (50), mapping quality (30), and 
genotype quality (9\0). Mutation variant “Alt-allele” calls 
had median 41% mean allele frequency. 
TCGA SNP array analysis
Level 2 and level 3 SNP array data were downloaded 
from TCGA data portal (http://cancergenome.nih.gov). 
For each probe, the ratio of normalized probe signal 
between tumor and the matched normal tissue was used 
to determine if there was a copy number alteration at 
the probe site. We considered a corresponding CNA at a 
site if tumor to normal ratio was >1.5 or <0.5. At each 
probe site, differential CNA between dMMR and pMMR 
tumors was calculated with Chi-squared analysis based on 
the 2 × 2 contingency table. If the expected values in the 
contingency table were less than 1, we used Fisher exact 
test following recommendations of Campbell et al. [71]. 
TCGA COAD whole genome sequence analysis
For 10 dMMR CRC patients with available whole 
genome sequencing tumor and matching normal germline 
DNA data, pre-processed BAM files were downloaded 
from TCGA database portal (http://cancergenome.nih.
gov). In addition, for 10 pMMR CRC patients, tumor and 
matching normal whole genome sequence data were also 
downloaded from TCGA and READ portals. The selection 
of these patients was based on matching sequence depth 
in addition to same sequencing center, to reduce potential 
batch effects. Somatic point mutations for each CRC patient 
were identified using Mutect [72] method by joint calling 
the TCGA pre-processed tumor and normal BAM files.
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